RUNX1 and myelodysplastic syndrome: RUNX1 reduces HIF-1α transcriptional activity to limit tumor angiogenesis and helps protect cells against oncogenesis (17). RUNX1 mutations are linked to increased illness and tumor progression in MDS and the removal of the DNA Damage response-mediated senescence barrier (17).